1. At the Forefront of Immunotherapy OTCQB: TPIV 1551 Eastlake Ave E Suite 100 Seattle, WA www.TapImmune.com

2. CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS Certain statements contained herein are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this document include, but are not limited to, statements relating to long-term stability, the Company's plan of operations and finances, the potential for the Company's vaccines and proposed clinical trials. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and that actual results may differ materially from estimates in the forward-looking statements. The Company undertakes no obligation to revise these forward-looking statements to reflect events or circumstances after the date hereof.

3. TAPIMMUNE INC. A New Frontier in Immunotherapy TapImmune is an Immunotherapy company specializing in the development of the most comprehensive and innovative immunotherapeutics in cancer and infectious diseases.

4. Opportunity & Milestones Why invest in TapImmune now? Unique and Broad product opportunities in cancer & infectious disease Two Phase I Clinical Trials ready to progress to Phase II HER2/neu breast cancer vaccine potential blockbuster Ovarian Cancer Urgently Needed Therapeutic with blockbuster potential HUGE market opportunities in multiple therapeutic indications PolyStart™ expression vector is a significant advance in vaccine technologies Strong management & advisory team Leverage of key collaborations with leading institutions Series of preclinical and clinical value inflexion points Significantly undervalued and poised for significant growth An approach with the potential to change lives and excellent entry level valuation

5. TAPIMMUNE Harnessing the Power of Immune System Leading Immunotherapy Approach: CANCER Making tumors visible to T-cells Stimulating T-killer cells AND T-helper cells Applicable to broad patient populations INFECTIOUS DISEASE Up-regulation of Antigen Presentation Stimulating T-killer cells & T-helper cells Applicable Multiple Infectious Diseases and Biothreats

6. The Immunotherapy Space New Frontier in Treatment of Cancer Immunotherapies Immune Checkpoint Blocade, Monoclonal antibodies (Roche) T-cell Therapies T-Cell Therapies Ex-Vivo: Adoptive T-cell transfer (LBIO;Juno); Dendritic cell transfer (NWBIO;DNDN; PBMD) In Vivo: Antigen stimulation (ONTY;GALE;IMUC) TapImmune is Unique: Platforms to stimulate BOTH Antigen presentation & T Cell stimulation (TPIV) GOAL: To Stimulate the Immune System to Effectively KILL Tumors

7. The TapImmune Approach Why we are different! Prime BOTH sides of the tumor Killing equation Proprietary peptide antigens used to stimulate a broad based T - Helper cell response (CD4) LONG-LIVED KILLER T-cells to actually KILL the tumor (CD8) These Proprietary Antigens allow us to treat: Wider patient populations (EG: +50% Vs Roche Herceptin 15%) Multiple Indications Multiple Therapeutic Areas (Cancer and Infectious Disease) SOLUTION: Most COMPREHENSIVE immunotherapeutic in development

8. Product Pipeline

9. Clincal Trial - Breast TPIV100/110 Trial 1: Her2neu Breast Cancer - Mayo Clinic Rochester MN HER2/neu positive breast cancer is one of most aggressive forms HER2/neu is overexpressed in ~ 30% breast cancer patients (total 220,000 /yr) Roche’s monoclonal antibody, Herceptin (current standard of care) can only treat ~ 20% of these patients (+$6 billion sales in 2013) Herceptin does not stimulate Killer T-cells – it slows/retards tumor growth In Contrast: We believe TapImmune’s comprehensive combination of Killers and Helpers has the potential to provide Long Lasting Immune Response in upto 84% of the HER2/neu positive patient population. A $ Multi-Billion product potential meeting an UNSATISFIED CLINICAL NEED in a very LARGE Market Herceptin Facts: Late Stage Survival improved by 4.5 Months. Early stage treatment resulted in a 9.5% improvement on recurrence. 70% of Her2neu+ patients do NOT respond to treatment

10. HER2/neu Clinical Status Her2neu Breast Cancer - Mayo Clinic Rochester MN Class II antigens (4 epitopes NPE) discovered in breast cancer patients - Clin. Cancer Res. (2010) 16, 825-83 22 Patients post Herceptin 6 x monthly intradermal + GMCSF Interim safety chectkpoint completed Positive Immune responses on first 6 patients (interim data) Excellent Results – Support progression to Phase ll Phase l Class II + Class I (p373-382) antigens (4+1) To start Q4, 2014 Small safety study 100-150 patient multicenter phase II Phase lb/ll

11. ImmunoTherapeutic TPIV110 Most Comprehensive Her2neu Breast Cancer Immunotherapeutic Peptide Antigens to stimulate BOTH: T-helper cells – Long Lasting Antigens discovered in breast cancer patients Naturally Processed Epitopes (NPE’s) Killer T-cells (p373-382) - Kills Tumor Cells Leading HER2/neu Vaccine Candidate in Development Compared to NeuVax by Galena: 4-5x greater KILLING activity against human tumor cell targets See: J.Immonol. (2013) 190, 479-488

12. Clinical Trial Ovarian TPIV200 Trial 2: Stage II/IIl Ovarian & Breast Cancer - Mayo Clinic MN Folate Receptor Alpha is expressed over 95% of ovarian cancers, for which the only treatment options are surgery and chemotherapy Very important and urgent clinical need for a new therapeutic. Time to recurrence is relatively short for this type of cancer and survival prognosis is extremely poor after recurrence. US alone, approximately 30,000 ovarian cancer patients newly diagnosed every year. Phase lb/2 advancement expected in late 2014. Orphan Drug Application – Pending FDA Another $ Multi-Billion product potential with an UNSATISFIED CLINICAL NEED URGENT CLINICAL NEED – LARGE MARKET – ORPHAN DRUG – FAST TRACK?

13. Clinical Trial Ovarian TPIV200 Trial 2: Stage II/IIl Ovarian & Breast Cancer - Mayo Clinic MN These Folate Alpha Antigens Also Applicable to Triple Negative Breast Cancer 23 patients with Stage II-III Breast, Ovarian, Peritoneal, Fallopian Tube Cancer Interim safety checkpoint completed Positive Immune responses observed Promising Interim Results – Support progression to Phase ll Phase ll Expected to Start in 2014 with Orphan Drug Application - FDA Pending

14. Collaborators & Scientific Advisors World Class Team Dr Keith Knutson (Vaccine & Gene Therapy Institute of Florida/Mayo Clinic): Director, Cancer Immunology and Immunotherapy Program, VGTI; Adjunct Faculty - Immunology, Mayo Clinic Dr Greg Poland: (Mayo Clinic) Head of Vaccines; Infectious disease/biodefense Dr Mac Cheever (Fred Hutchinson Cancer Research Center) Director Solid Tumor Research; Professor of Medicine/Oncology at the University of Washington (Seattle) & Director of the NCI-funded Cancer Immunotherapy Trials Network (CITN) Mark Reddish Advisor: Development, Board Product Development: Cancer vaccines and Biodefense: Biomira, ID Biomedical, Baxter, Bayer AG

15. Management And Advisors Mark Reddish Advisor: Development, Board 25 years experience in cancer vaccines and biodefense Biomira, ID Biomedical, Baxter, Bayer AG Denis Corin Corporate Finance Beckman Coulter, Novartis, MIV Therapeutics, Business Objects (PeopleSoft) Glynn Wilson, PhD CEO 25 years experience in product & corporate development SmithKline Beecham, Ciba-Geigy, Tacora Bob Florkiewicz, PhD Head of Research 25 years experience, academic and biotech Synergen, TSRI, UW, GSK, Seed IP Law Group

16. Cap Structure and Comps Reorganized Feb 2014 TPIV - TAPIMMUNE INC Capital Structure Shares Outstanding19,000,000 Public Float6,000,000 Market cap ~$25,000,000 Stock Price$1.25 Comparrisons in Immunotherapy and Biotech Shares OutMarket Cap Stock Price GALE (Galena)105,240,000$ 250,000,000 $2.50 LBIO (Lion Bio)26,000,000$ 180,000,000 $6.50 INO (Inovio)60,000,000$ 565,550,000 $10.30 DNDN (Dendreon)160,000,000$ 636,560,000 $1.40 NWBO (Nothwest Bio)53,400,000$ 355,730,000 $5.95

17. Opportunity & Milestones Why invest in TapImmune now? Unique and Broad product opportunities in cancer & infectious disease Two Phase I Clinical Trials ready to progress to Phase II HER2/neu breast cancer vaccine potential blockbuster Ovarian Cancer Urgently Needed Therapeutic with blockbuster potential HUGE market opportunities in multiple therapeutic indications PolyStart™ expression vector is a significant advance in vaccine technologies Strong management & advisory team Leverage of key collaborations with leading institutions Series of preclinical and clinical value inflexion points Significantly undervalued and poised for significant growth An approach with the potential to change lives and excellent entry level valuation

18. THANK YOU CONTACT: GLYNN WILSON Chief Executive Officer gwilson@tapimmune.com DENIS CORIN Corporate Finance dcorin@tapimmune.com OTCBB: TPIV